|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reteplase#Adult Indications and Dosage]] |
| {{Reteplase}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Indications And Usage==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| Retavase® (Reteplase) is indicated for use in the management of [[acute myocardial infarction ]](AMI) in adults for the improvement of ventricular function following [[AMI]], the reduction of the incidence of [[congestive heart failure]] and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms (see[[Reteplase clinical pharmacology|CLINICAL PHARMACOLOGY]]).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = | accessdate = }}</ref>
| | [[Category: Anticoagulants]] |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |